Press release Communiqué de presse

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter

Press release Communiqué de presse

April 10, 2001 10 April, 2001

Pheromone Sciences Corp Receives Approval for U.S. Pivotal Trial

Pheromone Sciences Corp (CDNX: PHS), today announced that it has received approval for its multi- center efficacy clinical trial of the PSC Fertility Monitor(tm).

The trial, to be carried out in 140 subjects, will take place at Duke University, Raleigh N.C., under the direction of Dr. Arthur Haney, Professor of Obstetrics and Gynecology and at Thomas Jefferson University Hospital in Philadelphia under the direction of Dr. Stephen Corson, Professor, Obstetrics and Gynecology and Section Head, Reproductive Endocrinology. Patient recruitment will commence later this month with the study scheduled to report in Q-4, 2001.

"With ever increasing numbers of women seeking assistance in order to achieve conception, the medical profession is constantly looking for innovative tools to assist in the process ", commented Duke University's Dr. Arthur Haney, Professor of Obstetrics and Gynecology. "As a non-invasive device that provides users with the opportunity to carry out home testing without urine or blood samples, the PSC Fertility Monitor offers a new level of convenience".

The U.S. study follows on the heels of the positive clinical results previously reported from a pilot study conducted at Toronto General Hospital under the direction of Dr. Robert Casper, Professor and Head of Reproductive Sciences at the University of Toronto. The trial demonstrated that the PSC Fertility Monitor' predicted ovulation within +/- 1.38 days of the actual date of ovulation, while also providing women with up to four days' advance notice. This accuracy compares favourably to other ovulation or fertility testing technologies and methods currently in use, none of which have the capacity to provide users with the same specific advance notice.

"We remain committed to our goal of filing submissions with the FDA for marketing approval on the PSC Fertility Monitor' prior to year end," said Christopher Neuman, President and Chief Executive Officer of Pheromone Sciences. "To this end we will diligently continue efforts towards the receipt of U.S. regulatory approval and commercialization in 2002".

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.